- Home
- RGC
as 11-15-2024 4:00pm EST
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
| Founded: | 2014 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 105.3M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 221.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $32.44 | Next Earning Date: | 11-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Regencell Bioscience Holdings Limited News
RGC Breaking Stock News: Dive into RGC Ticker-Specific Updates for Smart Investing
Simply Wall St.
21 days ago
Regencell Bioscience Holdings (NASDAQ:RGC) Is In A Good Position To Deliver On Growth Plans
Simply Wall St.
4 months ago
Regencell Bioscience Holdings Limited's (NASDAQ:RGC) most bullish insider, CEO Yat-Gai Au must be pleased with the recent 321% gain
PR Newswire
10 months ago
NuZee, Inc. Announces Receipt of NASDAQ Notification
Business Wire
10 months ago
Nukkleus Appoints C. Derek Campbell to Board of Directors, Bolstering its Growing Footprint in Emerging Markets
GlobeNewswire
10 months ago
Atlanticus Prices $50 Million Offering of Senior Notes
Thomson Reuters StreetEvents
10 months ago
Q4 2023 First Merchants Corp Earnings Call
Zacks
10 months ago
First Merchants (FRME) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
GlobeNewswire
10 months ago
Jeffs’ Brands Announces Pricing of $7.275 Million Private Placement
Compare RGC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGC Regencell Bioscience Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.